Totally Clinical: Trial Triumphs & Rad Trends

This week, Teckro Program Director Brian Deighan joins the podcast to talk about how sponsors are using Teckro to better engage their research sites. Brian explains how innovative approaches in sponsor communication improve relationships with investigators and discusses how surveys are an underutilized tool for sponsors to understand their sites.“Email chains for information can get lost, items can get misunderstood, or things may be taken out of context. Teckro and our survey functionality allows for that direct line to sites and really hearing everything firsthand.”

This week, Lexitas Pharma Services' George Magrath joins the podcast to discuss his unique dual perspective on patient care as both a CEO and a physician. George shares how his double role gives him a better understanding of patient needs and helps Lexitas to stand out in a competitive market. “I love taking care of patients. It's really quite a privilege and quite an honor to be able to do that. I think it keeps me really grounded with the purpose of what I'm doing, which is trying to advance our care.”

In this episode, freelance medical translator Ana Sofia Correia joins us to discuss the need for translation in clinical trials. She explains the risks if clinical trial material is biased towards English-speaking populations and the need for cultural sensitivity when translating content into local languages. Ana Sofia also reflects on the benefits AI could have on the industry and for translators.“While AI can be a powerful tool, it cannot replace human translators because there are still many aspects of translation that require human judgment and human expertise, such as the ability to understand those cultural nuances.”

Frances Reid, program director at the World Ovarian Cancer Coalition is back with an update on the Every Woman Study, the first of its kind to quantify global challenges women face with diagnosis and care access for ovarian cancer. Building on the survey's success, Frances explains how they have pivoted from online to other data capture methods with the help of healthcare providers in some of the most remote settings in the world. The stories she shares give us a glimpse into the incredible challenges women face in middle- and low-income countries. “It took 18 hours in an ambulance that she and her family had to pay for. And she received the surgery. And then she went home to recuperate, and the team were trying to encourage her to come back. But the woman and her family couldn't afford to raise the money to come back.”You can find out more information and follow the progress of the Every Woman Study here.

This episode we have something a little bit different as we talk with Karl McGrory, director of Europe at One Tree Planted. As an international nonprofit focused on reforestation, One Tree Planted has garnered widespread support from many sectors, including the pharmaceutical industry. Teckro has partnered with One Tree Planted and contributed to a project in Ireland, home to our HQ. Karl talks about Ireland's significant deforestation over the centuries and upcoming projects they have around the world.“There's an old folklore that said a squirrel could travel from the south of Ireland to the northern tip without touching the ground. That's how forested it was. So, it really is important that we restore some of the trees to that landscape.”

What risks pose the greatest threats to clinical research? This week, Jeanne Hecht of JTH Consulting joins us to answer this very question. During this episode, Jeanne talks about some of the current risks facing the life sciences industry and her concern about what the workforce shortage means to clinical research. Jeanne puts out a challenge to the industry to adopt a new mindset and think out of the box to attract talent in clinical research. “I think it's a challenge to each and every one of us to no longer be ok with the status quo. We need to constantly be looking within and externally to what we and others can be doing better to advance clinical research.”

Have you ever had a chance encounter that changed the course of your life? That's what happened to Danielle Mitchell, CEO of Black Women in Clinical Research. She discovered clinical research as a career path during a conversation at a pool party. After landing a clinical research coordinator role, she noticed the stark lack of diversity among staff. Since then, Danielle has been on a mission to educate and empower Black women to succeed in the industry. “A lot of times when I talk to my members, they will say that they stumbled upon clinical research and that's not the way it should be. We should be telling college students, telling everyone about clinical research as much as possible.”

This week Dr. Martine Dehlinger-Kremer, vice president, scientific affairs, pediatric subject matter expert at ICON, joins us for a deep dive into the inclusion of adolescents in clinical trials. Martine talks us through the considerations for including adolescents in adult clinical trials and how to overcome potential challenges. She also highlights disease areas where the inclusion of adolescents in adult trials has proved successful and why she is optimistic for the future. “Trial sponsors, investigators, regulators and ethics committees are encouraged to challenge research orthodoxy related to adolescent inclusion and adult research and seek trial solutions grounded in science rather than legal definition of age alone.”Dr. Martine Dehlinger-Kremer is also chair of the Children's Medicines Working Party at the European Forum for Good Clinical Practice, as well as chair of the Pediatric Working Group of the European CRO Federation.

This week we're joined by former CRA Maria Milas and site advocate Silvina Baudino to discuss how to make investigator meetings (IMs) more exciting. Attending an IM can mean endless PowerPoint presentations and days of repetitive meetings – but there is a better way. Maria and Silvina explain how by recasting the agenda for greater interaction, attendees will be more engaged and retain more about the study.  “It was four intense days of meetings of trainings, of talks from 8 a.m. to 6 p.m. every single day. Now, how does this look? Well, PowerPoint after PowerPoint after more PowerPoint.” 

Phase I oncology trials play a crucial role in drug development, yet they are extremely challenging for sites. To discuss this in greater detail, we're joined by Dan Otap, principal, alliance and partnerships lead at Genentech, and Jenn Weinberg, a veteran in oncology clinical trials. During the podcast, they delve into why early-stage oncology trials are so complex and ways to ease the burden on sites.“There's a level of safety and concern and risk that separates and creates a very distinct space when you're talking about early phase oncology. The fact that these patients that become brave participants on these trials are immunocompromised, severely sick, heavily pre-treated – you have a scenario fraught with potential complications.”As Dan discusses in the podcast, the Society for Clinical Research (SCRS) has recently launched a white paper on best practices to build out Phase I units in institutions.

Ashley Margo, founder of the The Clinical Research Circle, along with Teckro's Maria Milas, join us to discuss clinical research associate burnout. Earlier this year, they explained how CRA burnout is negatively affecting the industry. In this follow-up episode, they highlight solutions to reduce pressure and increase job satisfaction. “If you provide them with a tool that will suit their needs, their pains and their challenges will be just covered and fulfilled. So, what better than having a happy CRA who knows that they are supported by their CRO or by their sponsor?” 

When Writer Ira Feinstein was diagnosed with the BRCA1 breast cancer gene at just 20 years old, he was determined to learn everything he could about genetic research. Nearly a decade later, a landmark study led Ira to get a mastectomy and hysterectomy. During this podcast, Ira describes his unique patient journey, elaborating on the pitfalls of navigating the medical system as a trans man.“I looked at my medical records because I was moving from one cardiologist to another, and I noticed that they had ‘she' all over the notes. And it was a very strange experience because the doctor had been very welcoming, and he had said he had worked with trans patients before.”Contact Ira for speaking engagements and to learn more about his first book Cut Off.

This week we welcome Perla Nunes, community outreach director at Greater Gift. Ecuadorian-born Perla is passionate about diversity – with specific focus on the Hispanic community. During this episode, she explains how Greater Gift is encouraging a new generation of leaders from diverse backgrounds through its scholarship program and why bilingual staff are key to build trust among patients.“I always ask if studies are offered in Spanish. The response I always get is, 'yes, everything has been translated to Spanish, IRB approved, and they have everything set up in Spanish.' So my follow up question is: 'The enrollment sites, do they have bilingual staff?'"

This week, Ashley Margo, remote site monitor and founder of The Clinical Research Circle along with Teckro's Maria Milas, a former CRA, join the podcast to explain the impact of burnout on the clinical trial industry. Ashley and Maria talk about the problems presented with high CRA turnover and how this hinders site engagement and relationships.“If you get new CRAs on a regular basis on a study, it's going to be harder for the sponsor to create a relationship with the sites because the CRA is the person who represents the sponsor or the CRO when you get to sites.”

This week on the Totally Clinical podcast we've something rather special for the holiday season. But first, are you sitting comfortably? Draw the curtains, light a crackling fire and settle back to enjoy a nostalgic festive story with a Teckro twist – from our very own Chief Medical Officer Brendan Buckley… "A long grueling day and a tiring shift,  but Teckro was ready – this was our gift. A spring in our step, not a moment to lose, this was the time for excellent news..."

This week, we're joined by David Grew, a radiation oncologist and the founder of PRIMR – a platform that creates simple, illustrated videos to educate patients about cancer and clinical trials. During the podcast, David explains why he is transforming his “slapdash sketches” into video content and the power of video to help physicians communicate complex topics. “I said, 'Well, maybe I should just start converting these paper drawings into video assets so that we can kind of standardize this educational experience for our patients and introduce a lot more scale.'”

Diagnosed with a rare form of cancer in their late twenties, Stewart O'Callaghan was determined to make a difference for others. After the complexity of navigating the healthcare system as an LGBTQ+ patient, Stewart set up Live Through This, the UK's only charity that supports and advocates for LGBTQ+ people affected by cancer. Stewart discusses hopes and ambitions for the future and explains why people shouldn't fear “getting it wrong.” “There is a willingness to change, but a fear of getting it wrong. And I see this across research and health and third sector. I think a lot of people now understand that there is a duty to be representative of the general population or minoritized populations and there is a duty to have this intersectional lens.”

This week we host Roman Fishchuk, physician and principal investigator based in western Ukraine. Joining us moments after returning from an air raid shelter, Roman discusses life for the average person in Ukraine right now. He also describes keeping clinical trials going in a country at war and how Teckro becomes of even greater value in times of disruption.“We are really encouraging companies to come to, to resume their work in Ukraine, because right now, clinical trials are needed here more than ever.”

This week, Craig Lipset, advisor and founder at Clinical Innovation Partners, joins the podcast for a look into the future. Craig explains why he is optimistic for decentralized and hybrid models, considerations for more physicians to participate and the support the broader clinical trial ecosystem will need to ensure compliance and safety of clinical trials. “If decentralized can let us enable a visit to take place at home or in a pharmacy, how can decentralized enable us to host those study visits inside the offices of a treating physician in the community?”

When we first launched Totally Clinical: Trial Triumphs & Rad Trends as an industry podcast, we weren't sure what to expect. Now, with a wealth of amazing guests and compelling discussions, it is a hit! To celebrate 50 episodes in less than a year, host Hannah Lippitt and producer Conor Bryce sit down to discuss the journey. From pre-launch nerves to favorite episodes (too many to count!), take a peek behind the curtain and celebrate Totally Clinical at 50 with us. And of course, we couldn't have done it without you, the listeners. Here's to 50 more episodes!“We're seeing a tipping point where rather than us having to go out and search for guests, they're coming to us. It's getting to the place that we dreamed about, what we were first thinking about when we started.” - Conor"I feel that the podcast has really taken on a life of its own and is making its mark.” - Hannah

This week, we celebrate an exciting milestone as Totally Clinical hits its 50th episode. In the spirit of Teckro's core values: be responsive, do the right thing, and make an impact, CEO Gary Hughes joins us to discuss the issues that really matter. During the podcast, Gary explains how Teckro's One Tree Planted partnership supports biodiversity and the parallels with diversity and inclusion in clinical research.“I see a lot of parallels between what we're doing with One Tree Planted, their goals around biodiversity, and what we're trying to do with a digital-first approach, engaging more healthcare professionals in clinical research.”

Jimmy Bechtel, vice president of site engagement at the Society for Clinical Research Sites (SCRS), joins the podcast ahead of the flagship annual Global Site Solutions Summit in Florida. As SCRS marks its 10th anniversary, Jimmy reflects on milestones and accomplishments, including how SCRS is leading from the front on clinical trial diversity. Jimmy also shares his thoughts on the challenges that lie ahead.“We were one of the first organizations to recognize the need that was coming out of clinical trials for there to be a more diverse patient representation in the data and the outcomes of those clinical trials.”

Aaron Mann, co-founder of the Clinical Research Data Sharing Alliance (CRDSA), joins the podcast to discuss the importance of unleashing the power of clinical research data. Aaron explains why he's optimistic about the potential of data sharing among sponsors to revolutionize trial design and improve patient recruitment – and why he believes patients really want their data to be shared. "The question that CRDSA is really involved with is what happens after the trial? We know patients want their data to be used to further the science. It's why they join the clinical trial in the first place."

What if biopharma companies worked together to improve clinical trials for everyone? This is the vision of Virginia Nido – Roche's global head of industry collaboration. During this episode, Virginia explains how pre-competitive collaboration can address systemic challenges common to the industry and how to persuade big pharma companies to work together.“So, many of the collaborations that we participate in – as Roche and Genentech – are looking at things that we've always wanted to fix, sort of very basic things, like, 'Why do we collect investigator new information in 100 different ways?' Why can't we just all do that in the same way?”

We hear a lot about clinical trials and inclusion, but there is one group being left out of the conversation: sites. Affinity Health Chief Strategy Officer Bill Taaffe and Teckro's very own Brendan Buckley share what's really going on with sites.As a founding member of ICON who now works for a site, Bill shares his surprise at how little sites have input into clinical trial design and operations. The old friends cover a range of topics, including a site view on decentralized trials, site technology burden, and reimagining the CRA role.“The sites are excluded from all discussions on trial designs and technology being used. And it's mind boggling.”

How does the word “innovation” make you feel? Change can be scary, but opportunity lies in the new and unknown. Clinical trial innovation consultant Tom Julian joins Teckro's Global Head of Strategy Malia Lewin to discuss the advantages and complexities of clinical trial innovation. The pair explain why the industry needs to be agile, adaptable and open to change – truly using the power of innovation to revolutionize the patient experience.“We need to focus on both the really simple things as well as the complicated things, and always keep the patient in mind. And what do I mean by simple things? Can a visit be virtual? If so, make it a virtual visit. Why make someone drive or take off work when it's not needed?”

Clinical research is a conservative industry, but one man is using social media to shake things up. Brad Hightower, CEO of Hightower Clinical, is leveraging LinkedIn to prompt open – sometimes difficult – conversations between sites and sponsors. During this podcast, Brad discusses his desire to give sites an online voice and his hopes for greater industrywide progress. “I think it's important to continue to have these conversations in a very open and transparent manner. I think if we want to progress, that's what we need to do. They're not always comfortable.”

What can we do to tackle the workforce shortage in clinical research? This episode Judy Galindo and Monica Cuitiva, co-founders of Latinos in Clinical Research, join us to examine the potential solutions. During the podcast, the pair explain why education plays a pivotal role in raising awareness of the industry's potential, why sponsors, sites and CROs need to hire more entry-level staff, and emphasize the urgency for more resources to help train and retain staff."Online trainings are excellent, but also hands-on exposure; shadowing coordinators, research assistants, various other positions within – that's the training that's required to bring these people on, a combination of both."

What is the role of bioethics in medical decision-making? Here to explain more about this fascinating topic is Katrina Bramstedt, global head of bioethics at Roche. During this episode of the Totally Clinical podcast, Katrina discusses the crucial role bioethics has in the industry, why she believes every pharmaceutical company should have a bioethics department – and expands on how bioethics can support patient centricity."Patient centricity is very much connected to bioethics because we want to make products that patients actually need, not products that we think they need or we think might be nice to develop for whatever reason."

This week Robbyn Mattei, co-founder and director of Alpha Trials joins the Totally Clinical podcast from South Africa. Robbyn shares his insight into the developing clinical research landscape in the region and is passionate about increasing the viability of clinical trials in South Africa."In developing countries like South Africa, infrastructure and funding is severely limited, and this means we have fewer facilities that can accommodate clinical trials."

This week, Lilly Skok Bunch, executive director of the non-profit organization Greater Gift joins us to share the unique patient-oriented mission of showing gratitude to clinical trial participants. More than just a feel-good gesture, Lilly explains the tangible benefits for companies including Merck. Emboldened by their impact, Lilly also discusses how the Greater Good is looking to tackle clinical trial diversity, equity and inclusion."We are expressing gratitude to the medical heroes who clinical research could not happen without and we are also encouraging individuals to stay enrolled in the studies that they have been involved with."

This week on the Totally Clinical podcast we welcome Grayson Scott, clinical research coordinator and site supervisor at Centricity Research. This is a very special episode because we hear first hand from Grayson about how Teckro supports his day job. Grayson explains how Teckro helps him put the patient first with access to essential study content in the palm of his hand and elaborates on why more sponsor-to-site lines of communication are urgently needed…"I'm really excited about the communication possibilities with Teckro. I don't think currently that there are enough lines of communication open with sites to sponsors."

This week Jenn Weinberg joins us on the podcast. Jenn brings a wealth of experience working at industry giants including Novartis and GSK and now is rolling up her sleeves at Teckro on a mission to simplify oncology clinical trials. In our discussion, Jenn explains how she accidentally ended up working in oncology and recounts a patient conversation that continues to give her purpose. "I'm looking forward to seeing Teckro embedded in earlier stages of oncology trials to simplify the lives of everybody working on them – from CRAs, research sites, and even the global teams so they have better oversight on these important trials."

Taking part in a clinical trial can be a daunting experience - especially for those in underrepresented communities. This week, Steph Anderson, chief people officer at Meridian Clinical Research, joins us to discuss the importance of patient engagement with diverse communities to reduce obstacles and increase participation. Steph also discusses Merdian's new diversity initiative and explains why other companies shouldn't let perfection hold them back in tackling diversity, equity and inclusion."Walking into a study can be anxiety-inducing for anyone. When you add in the layer of not knowing if you are psychologically safe because you're in a minority or you've experienced bias, that can be an extra factor."

Silvina Baudino, our director of site engagement, is back on the Totally Clinical podcast! We last caught up in December last year – and she's been very busy since – spreading the word about our exciting new community for sites, Teckro Powered. From Texas to Florida, Silvina relays engaging tales from her travels, explaining how the Teckro Powered program can help support diversity, her big plans for the program's international expansion – and the popularity of the Teckro Powered blue T-shirt!“You know, we always shoot for the stars. We have the power to get there!”

This week on the Totally Clinical podcast we have a very special guest: Peter Gray, Teckro chairman. In honor of International Clinical Trials Day, Peter shares his industry insights and experiences from being associated with the pharmaceutical services industry for several decades. As the former CEO of ICON, one of the world's largest CROs, Peter elaborates on why he was inspired to join Teckro and shares what he sees for the future of clinical trials.“When they approached me to ask me to chair Teckro, I was an enthusiastic participant because I so profoundly believe that quality is essential in clinical research and making clinical research as accessible as possible for investigators, investigative sites and patients is essential for the advancement of human health.”

Many patients don't realize that clinical trials are a way to get tomorrow's treatments today. Joining us on the podcast to discuss this topic further, is Dr. Anne Mette Buhl, senior scientist at the Clearity Foundation, an advocacy group that improves the survival and quality of life of women suffering from ovarian cancer. Anne Mette talks us through the different phases of trials, the benefits of the Clearity clinical trials finder, and what patients need to be aware of when it comes to the eligibility criteria of oncology clinical trials. “A common misconception is that a clinical trial is something you consider once you have already used up all your other options – and I think that's very wrong.”

For many sites, retaining staff is difficult. The nature of the industry, trial complexity, costs and regulatory burden can lead to high levels of attrition and even burnout. However, one woman is on a mission to bring cultural change to sites. Nikki Osborn is CEO of Meridian Clinical Research – which she founded in 1999 and built up to a network of more than 30 research sites and 90 principal investigators. From charitable bucket lists to fleur-de-lis tokens, Nikki explains more about her goal to bring the power of positivity to sites.“We have the same struggles that a lot of people have when it comes to hiring and employee retention. And so what we've done is we try to think out of the box a little bit.”

Sustainability maybe isn't a word that you immediately associate with clinical trials. And the reality is that there are inefficiencies throughout the trial process that actually work against creating a greener planet. On World Earth Day, Jeanne Hecht of JTH Consulting and Teckro's Malia Lewin reflect on what sustainability means in clinical research and the impact of Teckro, including how more streamlined communications leads to less travel, more trial efficiency, and a greener approach.“Wow, this isn't just great for the environment. This is also amazing for the patient.” – Jeanne Hecht

Sonia Araujo discusses the incredibly moving blog she wrote about her aunt Lena's brain tumor diagnosis. From waking up one day with blurred vision to facing the terrible reality of grade 4 gliosarcoma – a rare type of brain cancer – Sonia elaborates on her aunt's journey."I find that people shy away from talking about these things and I think the opposite. I think we need to talk about these experiences, so there is more awareness."

This week we're joined by Silvina and Maria, both Teckro employees, as they compare notes on their past lives working in clinical research and reflect on the pivotal role of clinical research associates (CRAs). Silvina Baudino, Teckro director of site engagement, and Maria Milas, Teckro solutions consultant, talk about how CRAs are the “glue” of trials, overseeing multiple sites and building strong working relationships with research staff. With topics ranging from lifelong friendships made working in clinical research to the importance of trust and musings about technology and the future of the industry, Silvina and Maria draw on their experience to spotlight CRAs. "Just to give you an example, my best friend used to be a CRA when I was a study coordinator more than 20 years ago. That is the kind of relationship you sometimes have with your CRAs."

This week, Cindy Jackson, chief operating officer at the Institute for Advanced Clinical Trials in Children discusses the complex topic of pediatric drug development. From misunderstandings in designing clinical trials to the problem of "lag time" where children don't get access to treatments as quickly as adults, Cindy explains why the situation is unacceptable. As a champion for children's drug development, she outlines how things can change, starting with clinical trial referrals as an automatic part of children's patient care."This long lag time between adult approval and pediatric approval in the same indication can be upwards of a decade or even longer, and I find this statistic really sad."

For some physicians, the intense workload and pressures of clinical trial settings can become overwhelming. This week, Courtney Alexander, site supervisor, contract and budget manager at Centricity Research, explains how community-based research sites support physicians by freeing up time so they can focus on the most important part of clinical trials: the patient. During this podcast, Courtney touches on the crucial role of the coordinator to help physicians with “growing pains,” how Centricity's patient-centric approach helps sites meet key metrics like enrollment goals, and how community-based sites are increasing access to clinical trials for all."Everybody should have access to clinical trials – everybody. And everyone should know that clinical research is not a last option."

Pancreatic cancer is one of the deadliest forms of cancer. With a five-year survival rate of just 11%, a diagnosis has long been considered a death sentence.However, there is hope. Cassadie Moravek, a director of clinical trial operations at the Pancreatic Cancer Action Network, joins us to explain how genetic testing and biomarkers are changing the game for patients – and elaborates on ambitious plans to increase the survival rate to 20% by 2030."So many people don't realize the options available to them, even though genetic testing has made huge leaps forward in the last few years."

We talk to Daré Bioscience President and CEO Sabrina Johnson about her perspective on the advancements women have made in the biotech industry, why good things happen when we're not afraid to take a leap, and how adopting a mindful approach in our professional lives helps us separate legitimate progress from pointless activity.

What started as a slight tremor in her right hand led to a Friday afternoon neurologist consultation and the unwelcome discovery of Parkinson's disease at just 38 years old. Ten years later, full-time “eternal optimist” and determined advocate Cathy Molohan shares her thoughts on deep brain stimulation, why exercise is so important to manage symptoms and the never-ending quest for a Parkinson's cure.Below are links to more information on Parkinson's disease:Yuvedo FoundationWorld Parkinson's CoalitionPD Avengers“Normally we just see the numbers, we see the statistics, we see the results. I think it's essential to give Parkinson's a face and voice, and Parkinson's is a disease that can take away many people's ability or desire to speak out loud – to really be seen.”

The Union for International Cancer Control (UICC) holds its annual initiative World Cancer Day on February 4. Global health, medicine and clinical research communities unite to raise awareness, improve education around cancer risks and emphasize the need for early diagnosis. Today, over 80% of all countries have a National Cancer Control Plan compared to just 66% in 2013.On World Cancer Day 2022, UICC Campaign Manager Janine Huguenin joins us to discuss the ambitious "Close the Care Gap" campaign, with plans to bring equity to cancer health for all. From celebrating real-word progress and building stronger alliances to mobilizing politicians, celebrities and friends, Janine is determined to shake up the system for lasting change.“We will just do more than spreading the word. We're going to shout it out from the rooftops. We are going to build stronger alliances and innovative new collaborations, and then it's really about mobilizing our friends, engaging our community. It's about rallying everyone we know behind this common cause.”

Pharmaceutical executive and consultant Dairine Dempsey urges women not to second-guess their ability, stresses the importance of emotional intelligence in the workplace, and highlights the need to address the lack of female representation at a senior level.

With ethnic minorities representing as little as 2% of all clinical trial participants in the US, Van Johnson, VP of business development at Benchmark Research, talks about the pressing issues surrounding underserved communities. He advises on how to increase engagement by addressing fears and speaking the "right language" and shares his optimism for the future in closing the clinical trial gap.“The key to building trust is for the pharmaceutical companies, the CROs, and clinical research sites to understand and acknowledge inequities.”

In Totally Clinical's first podcast of 2022, an all-female star lineup from Teckro's leadership team discuss what they're excited about in the year ahead. They talk about encouraging the spirit of collaboration among sites, and the appeal of a hybrid approach to trials. They also delve into the future of personalized medicine and the post-COVID landscape for conferences. Sounds like 2022 will be a bumper year!"I'm interested to see how we define what a hybrid model is. It seems to be emerging as the preferred choice, so that things do not operate in the traditional way or don't go fully to a decentralized model, but somewhere in the middle." – Malian Lewin, Teckro Global Head of Strategy

We speak with Hillary Theakston, Executive Director of The Clearity Foundation. Hillary talks about her career motivations and reflects on the impact of her mentors. She also describes The Clearity Foundation and its role in guiding women with ovarian cancer to better clinical outcomes.